These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 18188512)

  • 21. Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes.
    Eikelboom JW; Weitz JI; Budaj A; Zhao F; Copland I; Maciejewski P; Johnston M; Yusuf S
    Eur Heart J; 2002 Nov; 23(22):1771-9. PubMed ID: 12419297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aspirin and clopidogrel treatment impair nitric oxide biosynthesis by platelets.
    O'Kane PD; Reebye V; Ji Y; Stratton P; Jackson G; Ferro A
    J Mol Cell Cardiol; 2008 Aug; 45(2):223-9. PubMed ID: 18606420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes.
    Mitsios JV; Papathanasiou AI; Elisaf M; Goudevenos JA; Tselepis AD
    Platelets; 2005 Aug; 16(5):287-92. PubMed ID: 16011979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-thrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta3 integrin in patients with coronary artery disease not being treated with aspirin.
    Dropinski J; Musial J; Jakiela B; Wegrzyn W; Sanak M; Szczeklik A
    Thromb Haemost; 2005 Dec; 94(6):1300-5. PubMed ID: 16411409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in plasma and platelet BDNF levels induced by S-citalopram in major depression.
    Serra-Millàs M; López-Vílchez I; Navarro V; Galán AM; Escolar G; Penadés R; Catalán R; Fañanás L; Arias B; Gastó C
    Psychopharmacology (Berl); 2011 Jul; 216(1):1-8. PubMed ID: 21308467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
    Kastrati A; von Beckerath N; Joost A; Pogatsa-Murray G; Gorchakova O; Schömig A
    Circulation; 2004 Oct; 110(14):1916-9. PubMed ID: 15262828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynamic platelet adhesion in patients with an acute coronary syndrome: The effect of antiplatelet therapy.
    Tsoumani ME; Tatsidou PT; Ntalas IV; Goudevenos JA; Tselepis AD
    Platelets; 2016 Dec; 27(8):812-820. PubMed ID: 27337147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.
    Siasos G; Oikonomou E; Zaromitidou M; Kioufis S; Kokkou E; Mourouzis K; Vlasis K; Vavuranakis M; Stone PH; Papavassiliou AG; Tousoulis D
    Atherosclerosis; 2015 Sep; 242(1):102-8. PubMed ID: 26188531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation.
    Kamath S; Blann AD; Chin BS; Lip GY
    J Am Coll Cardiol; 2002 Aug; 40(3):484-90. PubMed ID: 12142115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome.
    Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Romero-Barra M; Camoin L; Lambert M; Juhan-Vague I; Bonnet JL; Alessi MC
    Thromb Haemost; 2007 Feb; 97(2):212-7. PubMed ID: 17264949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over study.
    Eriksson AC; Jonasson L; Lindahl TL; Hedbäck B; Whiss PA
    J Transl Med; 2009 Jun; 7():42. PubMed ID: 19508722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical utility of remote platelet function measurement using P-selectin: assessment of aspirin, clopidogrel, and prasugrel and bleeding disorders.
    Bath PM; May J; Heptinstall S
    Platelets; 2018 Jul; 29(5):425-430. PubMed ID: 29667460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro effects of clopidogrel on the platelet-subendothelium interaction, platelet thromboxane and endothelial prostacyclin production, and nitric oxide synthesis.
    Arrebola MM; De la Cruz JP; Villalobos MA; Pinacho A; Guerrero A; Sánchez de la Cuesta F
    J Cardiovasc Pharmacol; 2004 Jan; 43(1):74-82. PubMed ID: 14668571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin.
    Storey RF; Judge HM; Wilcox RG; Heptinstall S
    Thromb Haemost; 2002 Sep; 88(3):488-94. PubMed ID: 12353080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.
    Vavuranakis M; Latsios G; Aggelis D; Bosinakou I; Karambelas I; Tousoulis D; Toutouzas K; Stefanadis C
    Clin Ther; 2006 Jun; 28(6):860-71. PubMed ID: 16860169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble P-selectin level correlates with acetylsalicylic acid but not with clopidogrel response in patients with stable coronary artery disease after a percutaneous coronary intervention.
    Kaufmann J; Wellnhofer E; Kappert K; Urban D; Meyborg H; Hauptmann T; Müller A; Meixner M; Graf K; Fleck E; Stawowy P
    Coron Artery Dis; 2013 Jun; 24(4):312-20. PubMed ID: 23549485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin.
    Undas A; Stepień E; Branicka A; Wołkow P; Zmudka K; Tracz W
    Kardiol Pol; 2009 Jun; 67(6):591-8. PubMed ID: 19618315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
    Schäfer A; Weinberger S; Flierl U; Eigenthaler M; Störk S; Walter U; Ertl G; Bauersachs J
    Thromb Haemost; 2008 Oct; 100(4):618-25. PubMed ID: 18841284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity.
    Harvey A; Modak A; Déry U; Roy M; Rinfret S; Bertrand OF; Larose É; Rodés-Cabau J; Barbeau G; Gleeton O; Nguyen CM; Proulx G; Noël B; Roy L; Paradis JM; De Larochellière R; Déry JP
    J Breath Res; 2016 Jan; 10(1):017104. PubMed ID: 26815196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease.
    Rao AK; Vaidyula VR; Bagga S; Jalagadugula G; Gaughan J; Wilhite DB; Comerota AJ
    Thromb Haemost; 2006 Dec; 96(6):738-43. PubMed ID: 17139367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.